Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | PTGES | O14684 | 1/20 | 0.40 |
| ▸ | GLS | O94925 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.38 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18087497 | 0.84 | CHRM3 (0.52) | CHRM3TP53ACKR3LMNAGAA | |
| SCHEMBL18083726 | 0.82 | GLS (0.45) | CHRM3TP53ACKR3PTGESGLS | |
| SCHEMBL18083787 | 0.82 | CHRM3 (0.52) | CHRM3TP53ACKR3MCHR1PTGES | |
| SCHEMBL18083727 | 0.80 | LMNA (0.50) | TP53LMNAGAAPTGESADORA3 | |
| SCHEMBL18083724 | 0.78 | CHRM3 (0.62) | CHRM3TP53ACKR3PTGS1 | |
| SCHEMBL12662464 | 0.74 | PARP1 (0.53) | CHRM3TP53PTGESAURKA | |
| SCHEMBL17554062 | 0.72 | BCL3 (0.58) | CHRM3GAARXFP1 | |
| SCHEMBL18083762 | 0.69 | RXFP1 (0.45) | CHRM3TP53ACKR3PTGESRXFP1 | |
| SCHEMBL18083711 | 0.69 | ABL1 (0.49) | TP53LMNAGAAPTGESPTGS1 | |
| SCHEMBL24694849 | 0.68 | CHRM3 (0.44) | CHRM3ACKR3MCHR1F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3271348-B1 | NEW FYN KINASE INHIBITORS | Rottapharm Biotech Srl (IT) | 2019-01-30 | — | — | EP | disclosed |
| US-20180111919-A1 | NEW FYN KINASE INHIBITORS | ROTTAPHARM BIOTECH S.R.L. (IT) | 2018-04-26 | — | — | US | disclosed |
| EP-3070084-A1 | NEW FYN KINASE INHIBITORS | Rottapharm Biotech S.r.l. (IT) | 2016-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180111919-A1 | NEW FYN KINASE INHIBITORS | FYN, LCK, LYN | CHRM3 2569/4885TP53 2939/4885ACKR3 533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.